Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_137
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2017English

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2016English

Real-Life Use of Bendamustine for B-Cell Non-Hodgkin Lymphoma in a Community Hospital in Japan-Retreatment With Bendamustine Is Safe and Feasible

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Combination of Gemcitabine and Cisplatin Is Highly Active in Women With Endometrial Carcinoma

Cancer
Cancer ResearchOncology
2010English

Simultaneous Diffuse Large B-Cell Lymphoma (Dlbcl) and Follicular Lymphoma (Fl) at the Diagnosis Has Similar Outcome as DLBCL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy